arrow
B

Benedetta Puccini

University of Florence
H指数:21
被引数:1,763

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma

RENOIR三期研究:利妥昔单抗-来那度胺对比利妥昔单抗作为复发/难治性滤泡性淋巴瘤的维持治疗

2026-09-010
PRE
Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial

自体移植后复发/难治性滤泡性淋巴瘤患者继发恶性肿瘤风险增加:FIL-FLAZ12 III期试验的长期结果

2026-08-120
OAAI
Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

症状性华氏巨球蛋白血症的肾功能不全:一项意大利全国多中心研究

2026-03-080
OAAI
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE-FIRST study

老年套细胞淋巴瘤患者中,首次进展时间和体能状态的作用:ELDERLY MANTLE-FIRST研究的结果

2025-12-010
OAAI
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study

利妥昔单抗、 bendamustine 和 cytarabine,随后使用 venetoclax 治疗高风险套细胞淋巴瘤老年患者(FIL_V-RBAC):一项多中心、单臂、Ⅱ期研究

2025-09-170
PRE
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a Fondazione Italiana Linfomi Cohort Study

R-miniCOMP与R-miniCHOP在老年非适合型弥漫大B细胞淋巴瘤患者中的比较疗效:来自意大利淋巴瘤基金会队列研究的见解

2025-05-130
PRE
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients

FIL MCL0208试验中,来那度胺维持治疗与观察在MCL患者自体干细胞移植(ASCT)后的长期结果

2025-03-220
OAAI
First-line treatment of Waldenstrom's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies
2024-11-190
OAAI
Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

V-Rbac背景下微小残留病评估,一项Fondazione Italiana Linfomi (FIL)风险定制II期临床试验

BLOOD
IF23.1
2024-11-050
PRE
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
2023-08-015
OAAI
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
2023-07-278
OAAI
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial
2023-07-181
OAAI
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
2023-04-014
OAAI
Ibrutinib in relapsed/refractory patients with Waldenstrom macroglobulinemia: a real-life, retrospective study on behalf of the RTL (regional Tuscan lymphoma network)
2023-02-031
PRE
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
2022-12-017
OAAI
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)
2022-11-1713
OAAI